A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

NCT05083585 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Prevention

Interventions

BIOLOGICAL: Ad26.RSV.preF-based vaccine

Sponsor

Janssen Vaccines & Prevention B.V.